Business
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results
Company launches rhCollagen-based BioInk platform with Collink.3D™ for use in 3D bioprinting of human tissues, scaffolds and organs REHOVOT, Israel, Nov. 18,
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"Company launches rhCollagen-based BioInk platform with Collink.3D™ for use in 3D bioprinting of human tissues, scaffolds and organs\n\n\nREHOVOT, Israel, Nov. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the third quarter ended September 30, 2021.\n\n \n \n \n \n \n \n\n \n\"The recent commercial launch of Collink.3D represents an important inflection point for CollPlant in its efforts to become a market leader in the field of regenerative medicine. Our unique rhCollagen-based BioInk is differentiated from other commercial bioinks by its bio-functionality, homogeneity, and increased safety profile\" said Yehiel Tal, CollPlant's Chief Executive Officer. \"Collink.3D, our first commercially available bioink, marks the continuation of the strong momentum and market validation we are seeing with our rhCollagen platform as exemplified by our co-development agreements with Allergan Aesthetics, an AbbVie company, and 3D Systems earlier in the year.\"\n Recent Corporate Highlights \nIn November 2021, CollPlant announced the commercial launch of a BioInk platform with Collink.3DTM for use in 3D bioprinting of human tissues, scaffolds and organs. Made from truly human collagen in plants, Collink.3D enables the production of scaffolds that accurately mimic the physical properties of human tissues and organs, with improved bio-functionality, safety and reproducibility. Biofabricated constructs using Collink.3D can be used in a variety of applications including drug discovery, drug screening, tissue testing as well as development and manufacturing of transplantable tissues, scaffolds and organs, representing a potential multi-billion dollar market opportunity. Continued to advance ongoing commercial partnership agreements signed earlier this year with both Allergan Aesthetics, and 3D Systems. The Company is working with Allergan to develop and commercialize dermal and soft tissue fillers for the medical aesthetics market as well as potentially other aesthetic products. CollPlant also continues to move forward with its co-development agreement with 3D Systems for a 3D bioprinted regenerative tissue matrix for use in breast...